{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:54:14Z","timestamp":1791996854367,"version":"4.4.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"MINECO\/AEI\/FEDER, UE","award":["MAT2013-43127-R"],"award-info":[{"award-number":["MAT2013-43127-R"]}]},{"name":"MINECO\/AEI\/FEDER, UE","award":["MAT2017-83858-C2-1"],"award-info":[{"award-number":["MAT2017-83858-C2-1"]}]},{"name":"Complutense University Research Group","award":["UCM-920415"],"award-info":[{"award-number":["UCM-920415"]}]},{"name":"Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en Oftalmolog\u00eda RETICS (Oftared)","award":["RD16\/0008 ISCIII-FEDER"],"award-info":[{"award-number":["RD16\/0008 ISCIII-FEDER"]}]},{"name":"Spanish Fund for Health Research","award":["PI17\/00079"],"award-info":[{"award-number":["PI17\/00079"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.addr.2018.01.007","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T18:05:39Z","timestamp":1515780339000},"page":"127-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina"],"prefix":"10.1016","volume":"126","author":[{"given":"Irene","family":"Bravo-Osuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Andr\u00e9s-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Arranz-Romera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Esteban-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene T.","family":"Molina-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Herrero-Vanrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2018.01.007_bb0005","first-page":"2109","article-title":"Current perspective of neuroprotection and glaucoma","volume":"9","author":"Tian","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.007_bb0010","first-page":"1","article-title":"Age-related macular degeneration and mortality: a systematic review and meta-analysis","author":"McGuinness","year":"2017","journal-title":"Ophthalmic Epidemiol."},{"key":"10.1016\/j.addr.2018.01.007_bb0015","first-page":"1","article-title":"Mini review: changes in the incidence of and progression to proliferative and sight-threatening diabetic retinopathy over the last 30\u202fyears","author":"Liew","year":"2017","journal-title":"Ophthalmic Epidemiol."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0020","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.preteyeres.2009.06.001","article-title":"Para-inflammation in the aging retina","volume":"28","author":"Xu","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2018.01.007_bb0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.preteyeres.2014.04.002","article-title":"The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies","volume":"42","author":"Herrero-Vanrell","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"issue":"4","key":"10.1016\/j.addr.2018.01.007_bb0030","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1167\/iovs.13-13707","article-title":"Drug and gene delivery to the back of the eye: from bench to bedside","volume":"55","author":"Rowe-Rendleman","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14712598.2016.1131265","article-title":"Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy","volume":"16","author":"Hussain","year":"2016","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0040","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s13346-016-0336-5","article-title":"Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases","volume":"6","author":"Bravo-Osuna","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2018.01.007_bb0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jconrel.2015.10.007","article-title":"Non-viral therapeutic approaches to ocular diseases: an overview and future directions","volume":"219","author":"Zulliger","year":"2015","journal-title":"J. Control. Release"},{"issue":"Pt B","key":"10.1016\/j.addr.2018.01.007_bb0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejpb.2014.12.022","article-title":"Treatment of ocular disorders by gene therapy","volume":"95","author":"Solinis","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0055","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1167\/iovs.09-4114","article-title":"Prevalence of early and late age-related macular degeneration in India: the INDEYE study","volume":"51","author":"Krishnan","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9827","key":"10.1016\/j.addr.2018.01.007_bb0065","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.01.007_bb0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.preteyeres.2016.04.008","article-title":"Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes","volume":"53","author":"Khan","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0075","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/bjo.2009.166975","article-title":"Current treatment options for retinal angiomatous proliferans (RAP)","volume":"94","author":"Gupta","year":"2010","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00006982-200502000-00002","article-title":"Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update","volume":"25","author":"Participants","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.addr.2018.01.007_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002030.pub2","article-title":"Photodynamic therapy for neovascular age-related macular degeneration","volume":"4","author":"Wormald","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0301-4738.36474","article-title":"Bevacizumab: off-label use in ophthalmology","volume":"55","author":"Grisanti","year":"2007","journal-title":"Indian J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0095","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.addr.2018.01.007_bb0100","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ajo.2006.05.061","article-title":"Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases","volume":"142","author":"Kaiser","year":"2006","journal-title":"Am J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2010.11.017","article-title":"Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file","volume":"151","author":"Brechner","year":"2011","journal-title":"Am J. Ophthalmol."},{"issue":"20","key":"10.1016\/j.addr.2018.01.007_bb0110","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.addr.2018.01.007_bb0115","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1517\/13543780903201684","article-title":"VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration","volume":"18","author":"Dixon","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"10 Suppl","key":"10.1016\/j.addr.2018.01.007_bb0120","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.ophtha.2009.06.049","article-title":"Antiangiogenic approaches to age-related macular degeneration in the future","volume":"116","author":"Do","year":"2009","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0125","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990\u20132010: a systematic analysis","volume":"1","author":"Bourne","year":"2013","journal-title":"Lancet Glob. Health"},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0130","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/IIO.0b013e31819fd5d7","article-title":"The role of genetics in susceptibility to diabetic retinopathy","volume":"49","author":"Liew","year":"2009","journal-title":"Int. Ophthalmol. Clin."},{"issue":"9","key":"10.1016\/j.addr.2018.01.007_bb0140","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2337\/db09-0059","article-title":"A systematic meta-analysis of genetic association studies for diabetic retinopathy","volume":"58","author":"Abhary","year":"2009","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.addr.2018.01.007_bb0145","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2337\/diab.46.11.1829","volume":"46","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.01.007_bb0150","doi-asserted-by":"crossref","first-page":"95103","DOI":"10.1155\/2007\/95103","article-title":"Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy","volume":"2007","author":"Kern","year":"2007","journal-title":"Exp. Diabetes Res."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0155","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000213639","article-title":"Microaneurysm turnover is a biomarker for diabetic retinopathy progression to clinically significant macular edema: findings for type 2 diabetics with nonproliferative retinopathy","volume":"223","author":"Nunes","year":"2009","journal-title":"Ophthalmologica"},{"issue":"10","key":"10.1016\/j.addr.2018.01.007_bb0160","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/archopht.1976.03910040540013","article-title":"Clinicopathologic correlations in diabetic retinopathy. I. Histology and fluorescein angiography of microaneurysms","volume":"94","author":"De Venecia","year":"1976","journal-title":"Arch. Ophthalmol."},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0165","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0002-9394(70)92273-7","article-title":"Correlation of fluorescein angiogram and retinal digest in diabetic retinopathy","volume":"69","author":"Kohner","year":"1970","journal-title":"Am J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0170","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","article-title":"Inflammation in diabetic retinopathy","volume":"30","author":"Tang","year":"2011","journal-title":"Prog. Retin. Eye Res."},{"issue":"14","key":"10.1016\/j.addr.2018.01.007_bb0175","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"7160","key":"10.1016\/j.addr.2018.01.007_bb0180","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.addr.2018.01.007_bb0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.addr.2018.01.007_bb0190","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.110.960120","article-title":"Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"122","author":"Mancia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.01.007_bb0195","first-page":"1","article-title":"Evidence-based treatment of diabetic retinopathy","author":"Rami","year":"2016","journal-title":"Semin. Ophthalmol."},{"issue":"12","key":"10.1016\/j.addr.2018.01.007_bb0200","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11892-016-0825-4","article-title":"Vascular endothelial growth factor inhibitors for diabetic retinopathy","volume":"16","author":"Dhoot","year":"2016","journal-title":"Curr. Diab. Rep."},{"issue":"16","key":"10.1016\/j.addr.2018.01.007_bb0205","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4239\/wjd.v7.i16.333","article-title":"Treatment of diabetic retinopathy: recent advances and unresolved challenges","volume":"7","author":"Stewart","year":"2016","journal-title":"World J. Diabetes"},{"issue":"9735","key":"10.1016\/j.addr.2018.01.007_bb0210","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.addr.2018.01.007_bb0215","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/138920211795860107","article-title":"Retinitis pigmentosa: genes and disease mechanisms","volume":"12","author":"Ferrari","year":"2011","journal-title":"Curr. Genomics"},{"issue":"9549","key":"10.1016\/j.addr.2018.01.007_bb0220","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis pigmentosa","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.addr.2018.01.007_bb0225","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.addr.2018.01.007_bb0230","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.addr.2018.01.007_bb0235","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1163\/156856207781494403","article-title":"Retinal prostheses: current challenges and future outlook","volume":"18","author":"Winter","year":"2007","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"4","key":"10.1016\/j.addr.2018.01.007_bb0240","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000354424","article-title":"Electronic approaches to restitute vision in patients with neurodegenerative diseases of the retina","volume":"50","author":"Stingl","year":"2013","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.addr.2018.01.007_bb0245","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.preteyeres.2015.06.005","article-title":"Pharmacological approaches to retinitis pigmentosa: a laboratory perspective","volume":"48","author":"Guadagni","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0250","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.addr.2018.01.007_bb0255","series-title":"Terminology and Guidelines for Glaucoma","author":"European Glaucoma Society","year":"2014"},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0260","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch. Ophthalmol."},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0265","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ophtha.2007.08.012","article-title":"Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma","volume":"115","author":"Medeiros","year":"2008","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.addr.2018.01.007_bb0270","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.ophtha.2011.01.047","article-title":"Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study","volume":"118","author":"Musch","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0275","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00401-016-1609-2","article-title":"Glaucoma: the retina and beyond","volume":"132","author":"Davis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0280","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/eye.2011.64","article-title":"Imaging apoptosis in the eye","volume":"25","author":"Cordeiro","year":"2011","journal-title":"Eye (Lond.)"},{"issue":"10","key":"10.1016\/j.addr.2018.01.007_bb0285","first-page":"771","article-title":"Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve","volume":"13","author":"Anderson","year":"1974","journal-title":"Investig. Ophthalmol."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0290","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.preteyeres.2011.11.002","article-title":"The molecular basis of retinal ganglion cell death in glaucoma","volume":"31","author":"Almasieh","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0295","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.preteyeres.2012.07.001","article-title":"Critical pathogenic events underlying progression of neurodegeneration in glaucoma","volume":"31","author":"Calkins","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0300","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.exer.2010.03.008","article-title":"Mitochondria: their role in ganglion cell death and survival in primary open angle glaucoma","volume":"90","author":"Osborne","year":"2010","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2018.01.007_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.06.003","article-title":"Glia-neuron interactions in the mammalian retina","volume":"51","author":"Vecino","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"issue":"11","key":"10.1016\/j.addr.2018.01.007_bb0310","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1\u20132","key":"10.1016\/j.addr.2018.01.007_bb0315","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijpharm.2016.01.020","article-title":"Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: state-of-the-art and challenges","volume":"499","author":"Ramazani","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"3\u20134","key":"10.1016\/j.addr.2018.01.007_bb0320","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drudis.2007.11.002","article-title":"Current and future ophthalmic drug delivery systems. A shift to the posterior segment","volume":"13","author":"Del Amo","year":"2008","journal-title":"Drug Discov. Today"},{"issue":"14","key":"10.1016\/j.addr.2018.01.007_bb0325","doi-asserted-by":"crossref","first-page":"ORSF5","DOI":"10.1167\/iovs.13-12789","article-title":"The prevalence of age-related eye diseases and visual impairment in aging: current estimates","volume":"54","author":"Klein","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.addr.2018.01.007_bb0330","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11095-008-9812-z","article-title":"Intraocular sustained-release delivery systems for triamcinolone acetonide","volume":"26","author":"Mansoor","year":"2009","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0335","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archopht.1992.01080140115038","article-title":"Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection","volume":"110","author":"Kwak","year":"1992","journal-title":"Arch. Ophthalmol."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0340","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1167\/iovs.15-18559","article-title":"Controlled release of dexamethasone from an intravitreal delivery system using porous silicon dioxide","volume":"57","author":"Hou","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.007_bb0345","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2015.05.279","article-title":"Novel biodegradable polyesteramide microspheres for controlled drug delivery in ophthalmology","volume":"211","author":"Andr\u00e9s-Guerrero","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.007_bb0350","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000431198","article-title":"Corticosteroids: triamcinolone, dexamethasone and fluocinolone","volume":"55","author":"C\u00e1ceres-del-Carpio","year":"2016","journal-title":"Dev. Ophthalmol."},{"issue":"12","key":"10.1016\/j.addr.2018.01.007_bb0355","first-page":"675","article-title":"Intravitreal bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulness for the treatment of diabetic macular edema","volume":"81","author":"Cardillo","year":"2006","journal-title":"Arch. Soc. Esp. Oftalmol."},{"issue":"10","key":"10.1016\/j.addr.2018.01.007_bb0360","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3109\/02713683.2010.497599","article-title":"Development of biodegradable controlled release scleral systems of triamcinolone acetonide","volume":"35","author":"Blatsios","year":"2010","journal-title":"Curr. Eye Res."},{"issue":"1\u20132","key":"10.1016\/j.addr.2018.01.007_bb0365","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijpharm.2012.05.025","article-title":"Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide","volume":"434","author":"Kadam","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0370","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1089\/jop.2011.0215","article-title":"Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration","volume":"28","author":"Zarei-Ghanavati","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0375","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0014-2999(01)01192-X","article-title":"Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells","volume":"425","author":"Bandi","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0380","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1167\/iovs.02-0791","article-title":"Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression","volume":"44","author":"Kompella","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1\u20133","key":"10.1016\/j.addr.2018.01.007_bb0385","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejphar.2004.07.046","article-title":"Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas","volume":"498","author":"Ayalasomayajula","year":"2004","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0390","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/jcp.10238","article-title":"Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier","volume":"195","author":"Saishin","year":"2003","journal-title":"J. Cell. Physiol."},{"issue":"7","key":"10.1016\/j.addr.2018.01.007_bb0395","first-page":"2462","article-title":"Quantitative assessment of the integrity of the blood-retinal barrier in mice","volume":"43","author":"Derevjanik","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0400","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0014-2999(02)02793-0","article-title":"Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model","volume":"458","author":"Ayalasomayajula","year":"2003","journal-title":"Eur. J. Pharmacol."},{"issue":"9444","key":"10.1016\/j.addr.2018.01.007_bb0405","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/S0140-6736(04)17265-6","article-title":"COX-2 inhibitors and risk of heart failure","volume":"364","author":"Kammerl","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0410","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1167\/iovs.05-0531","article-title":"Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage","volume":"47","author":"Amrite","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0415","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1167\/iovs.15-18213","article-title":"Ketorolac administration attenuates retinal ganglion cell death after axonal injury","volume":"57","author":"Nadal-Nicol\u00e1s","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"Pt B","key":"10.1016\/j.addr.2018.01.007_bb0420","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.visres.2015.02.001","article-title":"Photochemical approaches to vision restoration","volume":"111","author":"Van Gelder","year":"2015","journal-title":"Vis. Res."},{"issue":"7\u20138","key":"10.1016\/j.addr.2018.01.007_bb0425","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3109\/1061186X.2015.1060978","article-title":"Controlled release of photoswitch drugs by degradable polymer microspheres","volume":"23","author":"Groynom","year":"2015","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0430","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0168-3659(03)00194-9","article-title":"Biodegradable microspheres for protein delivery","volume":"90","author":"Sinha","year":"2003","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0435","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejpb.2004.10.006","article-title":"Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles","volume":"59","author":"Bilati","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"10","key":"10.1016\/j.addr.2018.01.007_bb0440","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1023\/A:1026498209874","article-title":"Protein instability in poly(lactic-co-glycolic acid) microparticles","volume":"17","author":"van de Weert","year":"2000","journal-title":"Pharm. Res."},{"issue":"1\u20132","key":"10.1016\/j.addr.2018.01.007_bb0445","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2007.05.067","article-title":"Improvement of a bovine serum albumin microencapsulation process by screening design","volume":"344","author":"Al Haushey","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.01.007_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/S0939-6411(98)00011-3","article-title":"Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactant","volume":"45","author":"Blanco","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.01.007_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2008.02.015","article-title":"Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres","volume":"69","author":"Garbayo","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.01.007_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2008.12.010","article-title":"Effective GDNF brain delivery using microspheres a promising strategy for Parkinson's disease","volume":"135","author":"Garbayo","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.007_bb0465","doi-asserted-by":"crossref","DOI":"10.1023\/A:1018820507379","article-title":"A novel system based on a poloxamer PLGA blend as a tetanus toxoid delivery vehicle","volume":"16","author":"Tob\u00edo","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.01.007_bb0470","doi-asserted-by":"crossref","DOI":"10.1002\/jps.20209","article-title":"Uniform encapsulation of stable protein nanoparticles produced by spray freezing for the reduction of burst release","volume":"94","author":"Leach","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.01.007_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2008.08.009","article-title":"Development of protein delivery microsphere system by a novel S\/O\/O\/W multi-emulsion","volume":"36","author":"Yuan","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.01.007_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2009.05.021","article-title":"Insulin nanoparticles preparation and encapsulation into poly(lactic-co-glycolic acid) microspheres by using an anhydrous system","volume":"378","author":"Han","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.01.007_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-3659(00)00326-6","article-title":"Protein encapsulation into biodegradable microspheres by a novel S\/O\/W emulsion method using poly(ethylene glycol) as a protein micronization adjuvant","volume":"69","author":"Morita","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.01.007_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2007.02.005","article-title":"Towards controlled release of BDNF manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain","volume":"119","author":"Koennings","year":"2007","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.addr.2018.01.007_bb0495","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1021\/mp400487f","article-title":"Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab","volume":"10","author":"Yandrapu","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2018.01.007_bb0500","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874364101206010054","article-title":"Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration","volume":"6","author":"Li","year":"2012","journal-title":"Open Ophthalmol. J."},{"issue":"9","key":"10.1016\/j.addr.2018.01.007_bb0505","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1021\/acs.molpharmaceut.6b00335","article-title":"PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of ranibizumab","volume":"13","author":"Elsaid","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2018.01.007_bb0510","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejpb.2016.09.003","article-title":"Study of stability and biophysical characterization of ranibizumab and aflibercept","volume":"108","author":"Moreno","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.addr.2018.01.007_bb0515","first-page":"653","article-title":"Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits","volume":"8","author":"Ye","year":"2015","journal-title":"Int. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.addr.2018.01.007_bb0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135608","article-title":"Coaxial electrospray of ranibizumab-loaded microparticles for sustained release of anti-VEGF therapies","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.addr.2018.01.007_bb0525","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1517\/14712598.5.11.1443","article-title":"Delivery of neurotrophic factors and therapeutic proteins for retinal diseases","volume":"5","author":"Thanos","year":"2005","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"5111","key":"10.1016\/j.addr.2018.01.007_bb0530","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0535","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1006\/bbrc.2000.2196","article-title":"Human glial cell-line-derived neurotrophic factor: a structure-function analysis","volume":"268","author":"Chen","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.addr.2018.01.007_bb0540","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0736-5748(00)00036-8","article-title":"Glial cell line-derived neurotrophic factor (GDNF) as a defensive molecule for neurodegenerative disease: a tribute to the studies of Antonia Vernadakis on neuronal-glial interactions","volume":"18","author":"Bohn","year":"2000","journal-title":"Int. J. Dev. Neurosci."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0545","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.exer.2010.08.009","article-title":"Neuroprotection in glaucoma - is there a future role?","volume":"91","author":"Baltmr","year":"2010","journal-title":"Exp. Eye Res."},{"issue":"1","key":"10.1016\/j.addr.2018.01.007_bb0550","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02741377","article-title":"GDNF: a novel factor with therapeutic potential for neurodegenerative disorders","volume":"19","author":"Walton","year":"1999","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0555","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/14737175.2016.1179582","article-title":"Exercise-induced neuroprotective effects on neurodegenerative diseases: the key role of trophic factors","volume":"16","author":"Campos","year":"2016","journal-title":"Expert. Rev. Neurother."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0560","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/1673-5374.177710","article-title":"Neurotrophic factor therapy for Parkinson's disease: past, present and future","volume":"11","author":"Sullivan","year":"2016","journal-title":"Neural Regen. Res."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0565","doi-asserted-by":"crossref","first-page":"331","DOI":"10.14336\/AD.2015.0825","article-title":"The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease","volume":"6","author":"Budni","year":"2015","journal-title":"Aging Dis."},{"issue":"11","key":"10.1016\/j.addr.2018.01.007_bb0570","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/mt.2010.167","article-title":"POD nanoparticles expressing GDNF provide structural and functional rescue of light-induced retinal degeneration in an adult mouse","volume":"18","author":"Read","year":"2010","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0575","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.exer.2010.08.022","article-title":"Trophic factors GDNF and BDNF improve function of retinal sheet transplants","volume":"91","author":"Yang","year":"2010","journal-title":"Exp. Eye Res."},{"issue":"1","key":"10.1016\/j.addr.2018.01.007_bb0580","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2011.06.023","article-title":"Retinal ganglion cells survival in a glaucoma model by GDNF\/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure","volume":"156","author":"Checa-Casalengua","year":"2011","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2018.01.007_bb0585","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/157339910790442619","article-title":"Emerging novel treatment strategies for diabetic eye diseases","volume":"6","author":"Osanai","year":"2010","journal-title":"Curr. Diabetes Rev."},{"issue":"11","key":"10.1016\/j.addr.2018.01.007_bb0590","first-page":"2724","article-title":"Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd\/rd mouse","volume":"40","author":"Frasson","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.addr.2018.01.007_bb0595","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0042-6989(97)00364-7","article-title":"Effects of GDNF on retinal ganglion cell survival following axotomy","volume":"38","author":"Koeberle","year":"1998","journal-title":"Vis. Res."},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0600","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/(SICI)1097-4695(19990215)38:3<382::AID-NEU7>3.0.CO;2-5","article-title":"Glial cell line-derived neurotrophic factor (GDNF) promotes the survival of axotomized retinal ganglion cells in adult rats: comparison to and combination with brain-derived neurotrophic factor (BDNF)","volume":"38","author":"Yan","year":"1999","journal-title":"J. Neurobiol."},{"issue":"6","key":"10.1016\/j.addr.2018.01.007_bb0605","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.exer.2009.08.014","article-title":"Delayed administration of glial cell line-derived neurotrophic factor (GDNF) protects retinal ganglion cells in a pig model of acute retinal ischemia","volume":"89","author":"Kyhn","year":"2009","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2018.01.007_bb0610","first-page":"1002","article-title":"Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1\/rd1 mouse","volume":"11","author":"Andrieu-Soler","year":"2005","journal-title":"Mol. Vis."},{"issue":"3","key":"10.1016\/j.addr.2018.01.007_bb0615","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jps.20629","article-title":"Neuroprotection of retinal ganglion cells in DBA\/2J mice with GDNF-loaded biodegradable microspheres","volume":"96","author":"Ward","year":"2007","journal-title":"J. Pharm. Sci. US"},{"key":"10.1016\/j.addr.2018.01.007_bb0620","first-page":"1783","article-title":"Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma","volume":"13","author":"Jiang","year":"2007","journal-title":"Mol. Vis."},{"issue":"1\u20132","key":"10.1016\/j.addr.2018.01.007_bb0625","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ijpharm.2012.07.019","article-title":"Preservation of biological activity of glial cell line-derived neurotrophic factor (GDNF) after microencapsulation and sterilization by gamma irradiation","volume":"436","author":"Checa-Casalengua","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.addr.2018.01.007_bb0630","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.biomaterials.2010.09.063","article-title":"Robust cell integration from co-transplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells","volume":"32","author":"Yao","year":"2011","journal-title":"Biomaterials"},{"issue":"Pt 18","key":"10.1016\/j.addr.2018.01.007_bb0635","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1242\/jeb.01049","article-title":"Erythropoietin and the hypoxic brain","volume":"207","author":"Marti","year":"2004","journal-title":"J. Exp. Biol."},{"issue":"4","key":"10.1016\/j.addr.2018.01.007_bb0640","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejps.2011.05.011","article-title":"Neuroprotective effect of erythropoietin-loaded composite microspheres on retinal ganglion cells in rats","volume":"43","author":"Rong","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0645","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12013-014-0259-z","article-title":"Erythropoietin (EPO) protects against high glucose-induced apoptosis in retinal ganglion cells","volume":"71","author":"Wang","year":"2015","journal-title":"Cell Biochem. Biophys."},{"issue":"10","key":"10.1016\/j.addr.2018.01.007_bb0650","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1167\/iovs.12-9898","article-title":"Effects of erythropoietin-dextran microparticle-based PLGA\/PLA microspheres on RGCs","volume":"53","author":"Rong","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2018.01.007_bb0655","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.2147\/IJN.S64100","article-title":"Safety evaluation of poly(lactic-co-glycolic acid)\/poly(lactic-acid) microspheres through intravitreal injection in rabbits","volume":"9","author":"Rong","year":"2014","journal-title":"Int. J. Nanomedicine"},{"issue":"30","key":"10.1016\/j.addr.2018.01.007_bb0660","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1016\/j.biomaterials.2013.06.044","article-title":"Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide","volume":"34","author":"Shmueli","year":"2013","journal-title":"Biomaterials"},{"issue":"Pt B","key":"10.1016\/j.addr.2018.01.007_bb0665","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ejpb.2014.12.005","article-title":"Sustained intravitreal delivery of connexin43 mimetic peptide by poly(d,l-lactide-co-glycolide) acid micro- and nanoparticles\u2013closing the gap in retinal ischaemia","volume":"95","author":"Chen","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.addr.2018.01.007_bb0670","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1167\/iovs.16-19300","article-title":"Intravitreal injection of proinsulin-loaded microspheres delays photoreceptor cell death and vision loss in the rd10 mouse model of retinitis pigmentosa","volume":"57","author":"Isiegas","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.addr.2018.01.007_bb0675","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1167\/iovs.08-2182","article-title":"Attenuation of vision loss and delay in apoptosis of photoreceptors induced by proinsulin in a mouse model of retinitis pigmentosa","volume":"49","author":"Corrochano","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.addr.2018.01.007_bb0680","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nn.2234","article-title":"Stimulation of the insulin\/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa","volume":"12","author":"Punzo","year":"2009","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0685","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/cne.21144","article-title":"Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: a morphological and ERG study","volume":"500","author":"Gargini","year":"2007","journal-title":"J. Comp. Neurol."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0690","first-page":"524","article-title":"Cellular response in subretinal neovascularization induced by bFGF-impregnated microspheres","volume":"40","author":"Kimura","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1\u20133","key":"10.1016\/j.addr.2018.01.007_bb0695","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0168-3659(01)00258-9","article-title":"Development of poly-(d,l-lactide-co-glycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis","volume":"72","author":"Cleland","year":"2001","journal-title":"J. Control. Release"},{"issue":"17","key":"10.1016\/j.addr.2018.01.007_bb0700","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1517\/14656566.2015.1100172","article-title":"Nonbiological pharmacotherapies for the treatment of diabetic macular edema","volume":"16","author":"Agarwal","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.addr.2018.01.007_bb0705","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17425247.2016.1213240","article-title":"Current advances in the treatment of neovascular age-related macular degeneration","volume":"14","author":"Villegas","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"issue":"5","key":"10.1016\/j.addr.2018.01.007_bb0710","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/IAE.0000000000001264","article-title":"Role of additional dexamethasone for the management of persistent or recurrent neovascular age-related macular degeneration under ranibizumab treatment","volume":"37","author":"Rezar-Dreindl","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.addr.2018.01.007_bb0715","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.12659\/MSM.895977","article-title":"Combination of aflibercept and bromfenac therapy in age-related macular degeneration: a pilot study aflibercept and bromfenac in AMD","volume":"21","author":"Wygledowska-Promienska","year":"2015","journal-title":"Med. Sci. Monit."},{"issue":"9","key":"10.1016\/j.addr.2018.01.007_bb0720","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3109\/02713683.2015.1101140","article-title":"Controlled and extended in vitro release of bioactive anti-vascular endothelial growth factors from a microsphere-hydrogel drug delivery system","volume":"41","author":"Osswald","year":"2016","journal-title":"Curr. Eye Res."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18300073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18300073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T03:13:24Z","timestamp":1654830804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X18300073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":144,"alternative-id":["S0169409X18300073"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2018.01.007","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2018.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}